

FILE 'REGISTRY' ENTERED AT 15:32:50 ON 02 APR 2009

EXP TELMESEIN/CN

L1 1 S E4

L2 1 S L1

FILE 'HCAPLUS' ENTERED AT 15:33:18 ON 02 APR 2009

L3 10 S L1

=> file registry
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FILE 'REGISTRY' ENTERED AT 15:32:50 ON 02 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 APR 2009 HIGHEST RN 1131012-40-2
DICTIONARY FILE UPDATES: 1 APR 2009 HIGHEST RN 1131012-40-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

```
=> exp telmesein/cn
E1      1      TELLUS TO 5/CN
E2      1      TELMESAN/CN
E3      0 --> TELMESEIN/CN
E4      1      TELMESTEINE/CN
E5      1      TELMICID/CN
E6      1      TELMID/CN
E7      1      TELMIDE/CN
E8      1      TELMIN/CN
E9      1      TELMIN B/CN
E10     1      TELMION/CN
E11     1      TELMISARTAN/CN
E12     1      TELMISARTAN GLUCURONIDE/CN
```

```
=> s e4
L1      1      TELMESTEINE/CN
```


```
=> s l1
L2      1      TELMESTEINE/CN
```

```
=> d l1
```

```
L1  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN  122946-43-4  REGISTRY
ED  Entered STN:  29 Sep 1989
CN  3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (R)-
OTHER NAMES:
CN  Telmesteine
FS  STEREOSEARCH
```

MF C7 H11 N O4 S
SR World Health Organization (WHO)
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CBNB, CHEMCATS, DDFU, DRUGU,
IMSPATENTS, IMSPRODUCT, IMSRESEARCH, MEDLINE, PHAR, PROUSDDR, PS,
TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcaplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
13.23	13.45

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 15:33:18 ON 02 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Apr 2009 VOL 150 ISS 14

FILE LAST UPDATED: 1 Apr 2009 (20090401/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1
L3 10 L1
=> d l3 1-10 ti abs bib hitstr

L3 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
TI In Silico Functional Profiling of Small Molecules and Its Applications
AB In silico screening is routinely used in the drug discovery process to predict whether each mol. in a database has a function of interest, such as inhibitory activity for a target protein. However, drugs generally have multiple functions including adverse effects. To obtain small mols. with desirable physiol. effects, it is useful to simultaneously predict as many functions as possible. The authors employed Support Vector Machine to build classification models for 125 mol. functions, derived from the MDDR database, which showed higher kappa statistics (0.775 on average) than those of predictions by Tanimoto similarity (0.708). By analyzing the patterns of the predicted values (functional profiles) of 871 marketed drugs, the authors demonstrated its applications to indication discovery, clustering of drugs, and detection of mol. actions related to adverse effects. The results showed that functional profiling can be a useful tool for identifying the multi-functionality or adverse effects of small mols.
AN 2008:1439962 HCAPLUS <<LOGINID::20090402>>
DN 150:89643
TI In Silico Functional Profiling of Small Molecules and Its Applications
AU Sato, Tomohiro; Matsuo, Yo; Honma, Teruki; Yokoyama, Shigeyuki
CS Department of Biophysics and Biochemistry, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
SO Journal of Medicinal Chemistry (2008), 51(24), 7705-7716
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT 122946-43-4
RL DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(in silico functional profiling of small mols. and its applications)
RN 122946-43-4 HCAPLUS
CN 3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Novel drug delivery system
AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or

modified release form. Present invention also relates to a process for preparing the said formulation.

AN 2007:1016569 HCAPLUS <<LOGINID::20090402>>

DN 148:503081

TI Novel drug delivery system

IN Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar

PA Torrent Pharmaceuticals Limited, India

SO Indian Pat. Appl., 80pp., Addn. of Indian Appl. No. 2004MU198.

CODEN: INXXBQ


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IN 2005MU01012	A	20070831	IN 2005-MU1012	20050826
PRAI	IN 2004-MU198	A0	20040220		
IT	122946-43-4, Telmestesteine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(novel drug delivery system)				
RN	122946-43-4 HCAPLUS				
CN	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)-			(CA INDEX NAME)	

Absolute stereochemistry.



L3 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN


TI Compositions comprising telmestesteine, glycyrrhetinic acid, and a proanthocyanidin for the treatment of inflammatory conditions of mucosae, skin and the eye

AB The present invention relates to compns. comprising telmestesteine, glycyrrhetinic acid, and a proanthocyanidin, as well as methods for using such compns. in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis(eczema), allergic contact dermatitis, seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. The present invention also relates to compns. comprising a proanthocyanidin, glycyrrhetinic acid and telmestesteine, as well as methods for using such compns. in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. Thus, a topical composition contained ethylhexyl palmitate 9.0, Butyrospermum parkii 6.0, pentylene glycol 5.0, arachidyl alc./behenyl alc. 4.0, arachidyl glucoside/glyceryl stearate/PEG-100 stearate 3.0, butylene glycol 3.0, glycyrrhetinic acid 2.0, capryloyl glycine 1.5, bisabolol 1.2, tocopheryl acetate 1.6, salicylic acid 1.0, NaOH 0.785, Carbomer 0.7, ethylhexyl glycerin 0.6, piroctone olamine 0.5, allantoin 0.35, DMDM hydantoin 0.3, proanthocyanidins from Vitis vinifera 0.1, disodium EDTA 0.08, tetrahexyldecyl ascorbate 0.05, Pr gallate 0.02,

telmesteine 0.01, and water 59.805%, resp.
 AN 2007:958801 HCAPLUS <<LOGINID:20090402>>
 DN 147:308200
 TI Compositions comprising telmesteine, glycyrrhetic acid, and a
 proanthocyanidin for the treatment of inflammatory conditions of mucosae,
 skin and the eye
 IN Mastrodonato, Marco; Ciattini, Roberto
 PA Sinclair Pharmaceuticals, Ltd., UK
 SO U.S., 13pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7262180	B2	20070828	US 2004-963848	20041012
	US 20050143324	A1	20050630		
	IT 2002MI0756	A1	20031009	IT 2002-MI756	20020409
	WO 2003084553	A1	20031016	WO 2003-EP3329	20030331
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20060247183	A1	20061102	US 2006-358747	20060221
	US 20080015155	A1	20080117	US 2007-841564	20070820
	US 20080114057	A1	20080515	US 2008-13244	20080111
PRAI	IT 2002-MI756	A	20020409		
	WO 2003-EP3329	A2	20030331		
	US 2004-963848	A1	20041012		
	US 2006-358747	B1	20060221		
IT	122946-43-4, Telmesteine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. comprising telmesteine, glycyrrhetic acid, and proanthocyanidin for treatment of inflammation of mucosa, skin and eye)				
RN	122946-43-4 HCAPLUS				
CN	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)- (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Novel dosage form
 AB A dosage form comprising of a high-dose, high-solubility active ingredient for

modified release and a low-dose active ingredient for immediate release wherein the weight ratio of immediate-release active ingredient and modified-release active ingredient is from 1:10 to 1:15000 and the weight of modified-release active ingredient per unit is from 500 mg to 1500 mg. A process for preparing the dosage form is provided.

AN 2007:769872 HCAPLUS <<LOGINID:20090402>>

DN 148:387155

TI Novel dosage form

IN Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar

PA Torrent Pharmaceuticals Limited, India

SO Indian Pat. Appl., 96pp.

CODEN: INXXBQ


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IN 2005MU01013	A	20070629	IN 2005-MU1013	20050826
PRAI	IN 2005-MU1013		20050826		
IT	122946-43-4, Telmesteine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(novel dosage form containing modified-release and immediate-release active ingredients)				
RN	122946-43-4 HCAPLUS				
CN	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)- (CA INDEX NAME)				

Absolute stereochemistry.



L3 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Steroids versus other immune modulators in the management of allergic dermatoses

AB Purpose of review: The classic role of topical and systemic corticosteroids for allergic dermatoses is discussed, with special attention to the impact on the current clin. treatment paradigm by newer systemic and topical therapies. These products are reviewed and recommendations presented on how to effectively assimilate them into clin. practice. Recent findings: Current knowledge about the etiopathogenesis of atopic dermatitis has resulted in drug development focused on agents with less toxicity than current topical and systemic corticosteroids. Some agents with ceramide/cholesterol/acid combinations demonstrate efficacy in restoring the dysfunctional skin barrier of atopic patients. Concerns: resulting from the recent Federal Drug Administration announcement regarding a theor. risk of cancer associated with topical calcineurin inhibitors are also addressed. Novel therapeutic entities are presented. Summary: Patients seeking relief from atopic dermatitis have historically had few really effective and safe therapeutic options. Topical calcineurin inhibitors represent an exciting new therapy for atopic dermatitis without the side-effect profile associated with topical corticosteroids. Nonsteroidal formulations incorporating glycyrrheticin

acid/telmestaine/Vitis vinifera extract and palmitoylethanolamide as 'active' ingredients recently entered the market, stressing antipruritic, antiinflammatory, and skin barrier repair. This confabulates against previously designed topical therapy paradigms. These new products may be used as monotherapy or alternatives to steroid agents.

AN 2007:526823 HCAPLUS <<LOGINID:20090402>>

DN 147:132531

TI Steroids versus other immune modulators in the management of allergic dermatoses

AU Abramovits, William; Perlmutter, Amy

CS Baylor University Medical Center, Dallas, TX, USA

SO Current Opinion in Allergy and Clinical Immunology (2006), 6(5), 345-354

CODEN: COACCS; ISSN: 1528-4050

PB Lippincott Williams & Wilkins

DT Journal; General Review

LA English

IT 122946-43-4, Telmestaine


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nonsteroidal formulations incorporating glycyrrhetic acid/telmestaine/Vitis vinifera extract and palmitoylethanolamide as 'active' ingredients may be used as alternatives to steroid agents in management of allergic dermatitis patient)

RN 122946-43-4 HCAPLUS

CN 3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 163 THERE ARE 163 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Atopiclair: its position within a topical paradigm for the treatment of atopic dermatitis

AB A review. Atopiclair and Zarzenda (glycyrrhetic acid/telmestaine/Vitis vinifera) are the brand names for a new topical agent for the treatment of atopic dermatitis and related eczemas. Its activity is purportedly the result of the action and interaction of several of its components, with the lack of any one constituent significantly compromising the efficacy of the end product. These compds. include glycyrrhetic acid, telmestaine, exts. from V. vinifera, combined with hyaluronic acid, shea butter from Butyrospermum parkii, and glycosaminoglycan for barrier repair purposes.

AN 2007:369732 HCAPLUS <<LOGINID:20090402>>

DN 147:85872

TI Atopiclair: its position within a topical paradigm for the treatment of atopic dermatitis

AU Abramovits, William; Perlmutter, Amy

CS Dermatology Treatment and Research Center, Dallas, TX, 75230, USA


SO Expert Review of Dermatology (2007), 2(2), 115-119

CODEN: ERDXAB; ISSN: 1746-9872

PB Future Drugs Ltd.

DT Journal; General Review
 LA English
 IT 122946-43-4, Telmesteine
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (active and inactive components of Atopiclair and Zarzenda including
 glycyrrhetic acid, telmesteine, extract from Vitis vinifera, hyaluronic
 acid and shea butter from Butyrospermum parkii were effective in
 patient with atopic dermatitis)
 RN 122946-43-4 HCAPLUS
 CN 3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Novel dosage form comprising modified-release and immediate-release active ingredients
 AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.
 AN 2006:100738 HCAPLUS <<LOGINID:20090402>>
 DN 144:198849
 TI Novel dosage form comprising modified-release and immediate-release active ingredients
 IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
 PA India
 SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446. CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060024365	A1	20060202	US 2005-134633	20050519
	IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
	IN 193042	A1	20040626		
	IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
	IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
	IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
	US 20040096499	A1	20040520	US 2003-630446	20030729
	IN 2002-MU697	A	20020805		
	IN 2002-MU699	A	20020805		
	IN 2003-MU80	A	20030122		
PRAI	IN 2003-MU82	A	20030122		

US 2003-630446 A2 20030729
 IT 122946-43-4, Telmesteine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel dosage form comprising modified-release and immediate-release
 active ingredients)
 RN 122946-43-4 HCAPLUS
 CN 3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Topical compositions comprising telmesteine for treating dermatological disorders
 AB This invention relates to topical compns., such as creams and lotions, that comprise telmesteine, or a salt thereof, as the active ingredient, and methods for their use in treating a variety of dermatol. diseases and disorders, including atopic dermatitis (eczema), allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopy. Thus, a formulation contained telmesteine 0.01, sodium hyaluronate 0.1, ethylhexyl palmitate 10.1, pentylene glycol 6.0, arachidyl alc. and behenyl alc. and arachidyl glycoside 4.5, glyceryl stearate and PEG-100 stearate 4.5, butylene glycol 4.5, capryloylglycine 2.5, tocopheryl acetate 1.2, Carbomer 1.7, ethylhexylglycerin 1.6, piroctone olamine 0.5, NaOH 0.387, allantoin 0.85, DMDM hydantoin 0.3, disodium EDTA 0.08, tetrahexyldecyl ascorbate 0.05, Pr gallate 0.02%, and water qs to 61.103%.
 AN 2005:369279 HCAPLUS <<LOGINID:20090402>>
 DN 142:417202
 TI Topical compositions comprising telmesteine for treating dermatological disorders
 IN Mastrodonato, Marco
 PA Sinclair Pharmaceuticals Limited, UK
 SO PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037275	A1	20050428	WO 2004-EP11228	20041007
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,			

	SN, TD, TG				
AU	2004281521	A1	20050428	AU 2004-281521	20041007
AU	2004281521	B2	20080417		
CA	2540859	A1	20050428	CA 2004-2540859	20041007
EP	1670464	A1	20060621	EP 2004-790183	20041007
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN	1863529	A	20061115	CN 2004-80029061	20041007
BR	2004015225	A	20061205	BR 2004-15225	20041007
JP	2007508264	T	20070405	JP 2006-530119	20041007
IN	2006DN01/763	A	20070831	IN 2006-DN1763	20060331
US	20070213381	A1	20070913	US 2007-575023	20070122
AU	2008203101	A1	20080807	AU 2008-203101	20080714
PRAI	IT 2003-MI1941	A	20031009		
	AU 2004-281521	A3	20041007		
	WO 2004-EP11228	W	20041007		
IT	122946-43-4, Telmestaine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(topical comps. comprising telmestaine for treating dermatol.				
	disorders)				
RN	122946-43-4 HCAPLUS				
CN	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)- (CA INDEX NAME)				

Absolute stereochemistry.




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
 AB Pharmaceutical comps. for the topical administration, comprising as active ingredients proanthocyanidins alone or combined with glycyrrhetinic acid, telmestaine, α -bisabolol or other components having complementary activity, in admixt. with a suitable carrier, useful for the treatment of a variety of pathologies such as atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia as well as for the treatment of mucosae inflammatory conditions.
 AN 2003:818299 HCAPLUS <<LOGINID::20090402>>
 DN 139:312465
 TI Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
 IN Mastrodonato, Marco; Ciattini, Roberto
 PA Sinclair Pharmaceuticals Limited, UK
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 2003084553	A1	20031016	WO 2003-EP3329	20030331
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IT 2002MI0756	A1	20031009	IT 2002-MI756	20020409
	CA 2481770	A1	20031016	CA 2003-2481770	20030331
	AU 2003226754	A1	20031020	AU 2003-226754	20030331
	AU 2003226754	B2	20070816		
	EP 1494692	A1	20050112	EP 2003-745775	20030331
	EP 1494692	B1	20070502		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009061	A	20050201	BR 2003-9061	20030331
	CN 1646151	A	20050727	CN 2003-807858	20030331
	JP 2005526822	T	20050908	JP 2003-581793	20030331
	AT 361084	T	20070515	AT 2003-745775	20030331
	NZ 535813	A	20070928	NZ 2003-535813	20030331
	ES 2285158	T3	20071116	ES 2003-745775	20030331
	RU 2320362	C2	20080327	RU 2004-129727	20030331
	MX 2004009755	A	20041213	MX 2004-9755	20041006
	NO 2004004259	A	20050106	NO 2004-4259	20041007
	ZA 2004008100	A	20060726	ZA 2004-8100	20041007
	US 7262180	B2	20070828	US 2004-963848	20041012
	US 20050143324	A1	20050630		
	US 20060247183	A1	20061102	US 2006-358747	20060221
	US 20080015155	A1	20080117	US 2007-841564	20070820
	US 20080114057	A1	20080515	US 2008-13244	20080111
PRAI	IT 2002-MI756	A	20020409		
	WO 2003-EP3329	W	20030331		
	US 2004-963848	A1	20041012		
	US 2006-358747	B1	20060221		
IT	122946-43-4, Telmesteine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical pharmaceutical compns. comprising proanthocyanidins for treatment of dermatitis)				
RN	122946-43-4 HCAPLUS				
CN	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)- (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat

AB The metabolism and disposition of telmesteine, a muco-active agent, have been investigated following single oral or i.v. administration of ¹⁴C-telmesteine in the Sprague-Dawley rat. ¹⁴C-telmesteine was rapidly absorbed after oral dosing (20 and 50 mg kg⁻¹) with an oral bioavailability of >90% both in male and female rats. The C_{max} and area under the curve of the radioactivity in plasma increased proportionally to the administered dose and those values in female rats were 30% higher than in male rats. 3. Telmesteine was distributed over all organs except for brain and the tissue/plasma ratio of the radioactivity 30 min after dosing was relatively low with a range of 0.1-0.8 except for excretory organs. Excretion of the radioactivity was 86% of the dose in the urine and 0.6% in the feces up to 7 days after oral administration. Biliary excretion of the radioactivity in bile duct-cannulated rats was about 3% for the first 24 h. The unchanged compound mainly accounted for the radioactivity in the urine and plasma. Telmesteine was hardly metabolized in microsomal incubations. A glucuronide conjugate was detected in the urine and bile, but the amount of glucuronide was less than 6% of excreted radioactivity.

AN 2003:603697 HCAPLUS <<LOGINID:20090402>>

DN 140:12437

TI Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat

AU Lee, J.; Son, J.; Rhee, S. W.; Kim, D. H.

CS Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology, Chungryang, Seoul, 136-791, S. Korea

SO Xenobiotica (2003), 33(7), 755-765

CODEN: XENOBH; ISSN: 0049-8254

PB Taylor & Francis Ltd.

DT Journal

LA English

IT 122946-43-4, Telmesteine 122946-43-4D, Telmesteine, glucuronide conjugates

RL: PKT (Pharmacokinetics); BIOL (Biological study)
(absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat)

RN 122946-43-4 HCAPLUS

CN 3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (4R)- (CA INDEX NAME)